Vistagen Reports Q3 Revenue of $303,000, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy VTGN?
Reports Q3 revenue $303,000, consensus $139,500. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational enhancements to our ongoing PALISADE-4 Phase 3 trial. We expect topline results from the randomized portion of PALISADE-4 in the first half of 2026," said Shawn Singh, President and Chief Executive Officer of Vistagen. "With outside collaborators and their proprietary artificial intelligence and machine learning methodologies, we are conducting an extensive analysis across all available PALISADE Program datasets to potentially inform modifications to the statistical analysis plan for PALISADE-4 and our regulatory strategy."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.516
Low
0.90
Averages
0.97
High
1.00
Current: 0.516
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statement Allegations: The complaint alleges that Vistagen made false and misleading statements, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies, which misled investors throughout the class period.
- Loss Recovery Opportunity: Investors suffered damages when the truth about Vistagen emerged, and the Schall Law Firm encourages affected shareholders to join the lawsuit to recover their losses, indicating potential significant financial liability for the company in the class action.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to contact them via phone or website to ensure proper legal representation in the class action and avoid being an absent class member.
See More
Vistagen Therapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Vistagen Therapeutics (NASDAQ: VTGN), encouraging those who purchased shares during the class period from April 1, 2024, to December 16, 2025, to contact the firm regarding potential lead plaintiff appointment.
- Poor Trial Results: On December 17, 2025, Vistagen announced that its PALISADE-3 trial for fasedienol, aimed at treating social anxiety disorder, failed to show statistically significant improvement on its primary endpoint, causing the stock price to plummet from $4.36 to $0.86, a decline exceeding 80%.
- Shareholder Registration Deadline: Shareholders must register by March 16, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress through portfolio monitoring software.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to false statements or omissions by companies, emphasizing the need for responsible business practices.
See More
Vistagen Class Action Notice for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to participate in the class action and protect their rights.
- Fee Structure: Investors joining the Vistagen class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors and encourages more victims to seek compensation.
- Case Background: The lawsuit alleges that Vistagen misled investors regarding its drug fasedienol's development, claiming positive outcomes from clinical trials while concealing significant adverse facts related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and strength in handling such cases.
See More
Vistagen Therapeutics Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Vistagen stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding Vistagen's drug fasedienol, despite significant adverse facts in the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, and ranked first by ISS for the number of settlements in 2017, underscoring its expertise and influence in the field.
- Investor Advisory: Investors are advised to carefully select qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal support and maximize potential recovery in the class action.
See More
Class Action Filed Against Vistagen Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Vistagen Therapeutics, seeking damages for investors who purchased securities between April 1, 2024, and December 16, 2025, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that Vistagen made materially false and misleading statements throughout the class period, particularly regarding the development and prospects of its drug fasedienol, severely undermining investor confidence in the company's future.
- Legal Consequences for Investors: Investors have until March 16, 2026, to apply as lead plaintiffs to participate in potential recoveries, highlighting the importance of legal proceedings in protecting investor rights.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is renowned for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions and its commitment to restoring investor capital and ensuring corporate accountability.
See More
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statements Allegation: The complaint alleges that Vistagen made false and misleading statements to the market, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies.
- Investor Losses: When the market learned the truth about Vistagen, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, adversely affecting investor decisions.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to proactively reach out for free legal consultations to discuss their rights before the class action is certified, ensuring investors can effectively protect their interests.
See More
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statement Allegations: The complaint alleges that Vistagen made false and misleading statements, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies, which misled investors throughout the class period.
- Loss Recovery Opportunity: Investors suffered damages when the truth about Vistagen emerged, and the Schall Law Firm encourages affected shareholders to join the lawsuit to recover their losses, indicating potential significant financial liability for the company in the class action.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to contact them via phone or website to ensure proper legal representation in the class action and avoid being an absent class member.
See More
Vistagen Therapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Vistagen Therapeutics (NASDAQ: VTGN), encouraging those who purchased shares during the class period from April 1, 2024, to December 16, 2025, to contact the firm regarding potential lead plaintiff appointment.
- Poor Trial Results: On December 17, 2025, Vistagen announced that its PALISADE-3 trial for fasedienol, aimed at treating social anxiety disorder, failed to show statistically significant improvement on its primary endpoint, causing the stock price to plummet from $4.36 to $0.86, a decline exceeding 80%.
- Shareholder Registration Deadline: Shareholders must register by March 16, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress through portfolio monitoring software.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to false statements or omissions by companies, emphasizing the need for responsible business practices.
See More
Vistagen Class Action Notice for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to participate in the class action and protect their rights.
- Fee Structure: Investors joining the Vistagen class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors and encourages more victims to seek compensation.
- Case Background: The lawsuit alleges that Vistagen misled investors regarding its drug fasedienol's development, claiming positive outcomes from clinical trials while concealing significant adverse facts related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and strength in handling such cases.
See More
Vistagen Therapeutics Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Vistagen stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding Vistagen's drug fasedienol, despite significant adverse facts in the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, and ranked first by ISS for the number of settlements in 2017, underscoring its expertise and influence in the field.
- Investor Advisory: Investors are advised to carefully select qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal support and maximize potential recovery in the class action.
See More
Class Action Filed Against Vistagen Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Vistagen Therapeutics, seeking damages for investors who purchased securities between April 1, 2024, and December 16, 2025, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that Vistagen made materially false and misleading statements throughout the class period, particularly regarding the development and prospects of its drug fasedienol, severely undermining investor confidence in the company's future.
- Legal Consequences for Investors: Investors have until March 16, 2026, to apply as lead plaintiffs to participate in potential recoveries, highlighting the importance of legal proceedings in protecting investor rights.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is renowned for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions and its commitment to restoring investor capital and ensuring corporate accountability.
See More
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statements Allegation: The complaint alleges that Vistagen made false and misleading statements to the market, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies.
- Investor Losses: When the market learned the truth about Vistagen, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, adversely affecting investor decisions.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to proactively reach out for free legal consultations to discuss their rights before the class action is certified, ensuring investors can effectively protect their interests.
See More
